469 related articles for article (PubMed ID: 17497097)
1. Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma.
Schütze C; Dörfler A; Eicheler W; Zips D; Hering S; Solca F; Baumann M; Krause M
Strahlenther Onkol; 2007 May; 183(5):256-64. PubMed ID: 17497097
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of the epidermal growth factor receptor tyrosine kinase by BIBX1382BS and the improvement of growth delay, but not local control, after fractionated irradiation in human FaDu squamous cell carcinoma in the nude mouse.
Baumann M; Krause M; Zips D; Eicheler W; Dörfler A; Ahrens J; Petersen C; Brüchner K; Hilberg F
Int J Radiat Biol; 2003 Jul; 79(7):547-59. PubMed ID: 14530164
[TBL] [Abstract][Full Text] [Related]
3. Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC.
Krause M; Schütze C; Petersen C; Pimentel N; Hessel F; Harstrick A; Baumann M
Radiother Oncol; 2005 Feb; 74(2):109-15. PubMed ID: 15734198
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant inhibition of the epidermal growth factor receptor after fractionated irradiation of FaDu human squamous cell carcinoma.
Krause M; Hessel F; Zips D; Hilberg F; Baumann M
Radiother Oncol; 2004 Jul; 72(1):95-101. PubMed ID: 15236881
[TBL] [Abstract][Full Text] [Related]
5. Effect of the hypoxic cell sensitizer isometronidazole on local control of two human squamous cell carcinomas after fractionated irradiation.
Schreiber A; Krause M; Zips D; Dörfler A; Richter K; Vettermann S; Petersen C; Beuthien-Baumann B; Thümmler D; Baumann M
Strahlenther Onkol; 2004 Jun; 180(6):375-82. PubMed ID: 15175873
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ("Iressa") and trastuzumab ("Herceptin").
Fukutome M; Maebayashi K; Nasu S; Seki K; Mitsuhashi N
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):528-36. PubMed ID: 16965995
[TBL] [Abstract][Full Text] [Related]
7. Response of human squamous cell carcinoma xenografts of different sizes to irradiation: relationship of clonogenic cells, cellular radiation sensitivity in vivo, and tumor rescuing units.
Baumann M; Dubois W; Suit HD
Radiat Res; 1990 Sep; 123(3):325-30. PubMed ID: 2145606
[TBL] [Abstract][Full Text] [Related]
8. Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation.
Krause M; Ostermann G; Petersen C; Yaromina A; Hessel F; Harstrick A; van der Kogel AJ; Thames HD; Baumann M
Radiother Oncol; 2005 Aug; 76(2):162-7. PubMed ID: 16024114
[TBL] [Abstract][Full Text] [Related]
9. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec).
Oertel S; Krempien R; Lindel K; Zabel A; Milker-Zabel S; Bischof M; Lipson KE; Peschke P; Debus J; Abdollahi A; Huber PE
Strahlenther Onkol; 2006 Jul; 182(7):400-7. PubMed ID: 16826359
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the response of human FaDu squamous cell carcinoma in nude mice after hypofractionated-accelerated regimens and "curative" fractionation schedules.
Appold S; Baumann M; Petersen C; Horn K; Eichhorn F
Strahlenther Onkol; 1998 Jun; 174(6):315-9. PubMed ID: 9645213
[TBL] [Abstract][Full Text] [Related]
11. Impact of the tumour bed effect on microenvironment, radiobiological hypoxia and the outcome of fractionated radiotherapy of human FaDu squamous-cell carcinoma growing in the nude mouse.
Zips D; Eicheler W; Brüchner K; Jackisch T; Geyer P; Petersen C; van der Kogel AJ; Baumann M
Int J Radiat Biol; 2001 Dec; 77(12):1185-93. PubMed ID: 11747543
[TBL] [Abstract][Full Text] [Related]
12. Impact of overall treatment time of fractionated irradiation on local control of human FaDu squamous cell carcinoma in nude mice.
Baumann M; Liertz C; Baisch H; Wiegel T; Lorenzen J; Arps H
Radiother Oncol; 1994 Aug; 32(2):137-43. PubMed ID: 7972907
[TBL] [Abstract][Full Text] [Related]
13. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).
Huang SM; Li J; Armstrong EA; Harari PM
Cancer Res; 2002 Aug; 62(15):4300-6. PubMed ID: 12154033
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer.
Shintani S; Li C; Mihara M; Terakado N; Yano J; Nakashiro K; Hamakawa H
Int J Cancer; 2003 Dec; 107(6):1030-7. PubMed ID: 14601066
[TBL] [Abstract][Full Text] [Related]
15. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor.
Solomon B; Hagekyriakou J; Trivett MK; Stacker SA; McArthur GA; Cullinane C
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(3):713-23. PubMed ID: 12573759
[TBL] [Abstract][Full Text] [Related]
16. Impact of increased cell loss on the repopulation rate during fractionated irradiation in human FaDu squamous cell carcinoma growing in nude mice.
Hessel F; Petersen C; Zips D; Krause M; Pfitzmann D; Thames HD; Baumann M
Int J Radiat Biol; 2003 Jul; 79(7):479-86. PubMed ID: 14530155
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.
Pollack VA; Savage DM; Baker DA; Tsaparikos KE; Sloan DE; Moyer JD; Barbacci EG; Pustilnik LR; Smolarek TA; Davis JA; Vaidya MP; Arnold LD; Doty JL; Iwata KK; Morin MJ
J Pharmacol Exp Ther; 1999 Nov; 291(2):739-48. PubMed ID: 10525095
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
20. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
